

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

<hr/>	:	MDL NO. 2724
IN RE: GENERIC DIGOXIN AND	:	16-MD-2724
DOXYCYCLINE ANTITRUST LITIGATION	:	
<hr/>	:	
	:	HON. CYNTHIA M. RUFÉ
THIS DOCUMENT RELATES TO:	:	
	:	
<i>ALL ACTIONS</i>	:	
<hr/>	:	

**PRETRIAL ORDER NO. 20
(COMMENT PERIOD FOR DRAFT ELECTRONIC CASE MANAGEMENT ORDER)**

AND NOW, this 19th day of May 2017, it is hereby **ORDERED** that the Court intends to enter a pretrial order setting forth the structure of the docketing and filing of documents in the MDL. In this instance, and to assist the efficient organization of the expanded MDL, the Court has determined that it is appropriate to provide counsel an opportunity to comment or object to the order before it is entered. Therefore, counsel may file comments or objections to the attached draft First Electronic Case Management Order no later than **May 26, 2017**.

It is so **ORDERED**.

BY THE COURT:


CYNTHIA M. RUFÉ, J.

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL 2724
16-MD-2724

HON. CYNTHIA M. RUFÉ

THIS DOCUMENT RELATES TO:

ALL ACTIONS

PRETRIAL ORDER NO. xx
(FIRST ELECTRONIC CASE MANAGEMENT PROTOCOL ORDER)

AND NOW, this day of May 2017, in order to promote the efficient management of this MDL, it is hereby **ORDERED** that the Court establishes the following protocol to govern the structure of the dockets and the filing of documents.

STRUCTURE OF THE DOCKETS

1. The “Master Docket,” 16-MD-2724, includes all generic pharmaceuticals pricing antitrust cases filed in or transferred to this Court as part of MDL 2724.
2. The Court has directed the Clerk of Court to establish “Lead Cases,” a general case for each pharmaceutical included in the MDL.
3. The Lead Cases include “Class Cases” for each putative class, or group, of Plaintiffs. The Court has directed the Clerk of Court to establish Class Cases for each pharmaceutical for the Direct Purchaser Plaintiffs (“DPPs”), End-Payer Plaintiffs (“EPPs”), and Indirect Reseller Plaintiffs (“IRP”). If there is no pending Class Case for a Plaintiff group for a particular pharmaceutical, the Class Case will serve as a placeholder for a possible later filing.
4. Each Class Case includes the applicable originally-filed “Individual Cases” that have been filed; these cases will retain their individual case numbers at this time.

DRAFT PROPOSED PRETRIAL ORDER

5. The Clerk of Court has established the following Lead Cases and Class Cases for docketing purposes:

Pharmaceutical	Lead Case	Direct Purchaser	End-Payer	Indirect Reseller
Albuterol	16-AL-27240	16-AL-27241	16-AL-27242	16-AL-27243
Amitriptyline	16-AM-27240	16-AM-27241	16-AM-27242	16-AM-27243
Baclofen	16-BC-27240	16-BC-27241	16-BC-27242	16-BC-27243
Benazepril HCTZ	16-BZ-27240	16-BZ-27241	16-BZ-27242	16-BZ-27243
Clobetasol	16-CB-27240	16-CB-27241	16-CB-27242	16-CB-27243
Clomipramine	16-CM-27240	16-CM-27241	16-CM-27242	16-CM-27243
Desonide	16-DS-27240	16-DS-27241	16-DS-27242	16-DS-27243
Digoxin	16-DG-27240	16-DG-27241	16-DG-27242	16-DG-27243
Divalproex ER	16-DV-27240	16-DV-27241	16-DV-27242	16-DV-27243
Doxycycline	16-DX-27240	16-DX-27241	16-DX-27242	16-DX-27243
Econazole nitrate	16-EC-27240	16-EC-27241	16-EC-27242	16-EC-27243
Fluocinonide	16-FL-27240	16-FL-27241	16-FL-27242	16-FL-27243
Glyburide	16-GL-27240	16-GL-27241	16-GL-27242	16-GL-27243
Levothyroxine	16-LV-27240	16-LV-27241	16-LV-27242	16-LV-27243
Lidocaine/Prilocaine	16-LD-27240	16-LD-27241	16-LD-27242	16-LD-27243
Pravastatin	16-PV-27240	16-PV-27241	16-PV-27242	16-PV-27243
Propranolol	16-PP-27240	16-PP-27241	16-PP-27242	16-PP-27243
Ursodiol	16-UR-27240	16-UR-27241	16-UR-27242	16-UR-27243

DRAFT PROPOSED PRETRIAL ORDER

6. The docketing structure allows for the possibility of the filing or transfer of cases naming additional pharmaceuticals or Plaintiff groups.

FILING OF DOCUMENTS

7. Unless otherwise ordered by the Court, only documents that relate to all actions may be filed on the Master Docket, and shall be captioned as follows:

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL 2724
16-MD-2724**

HON. CYNTHIA M. RUFE

THIS DOCUMENT RELATES TO:

ALL ACTIONS

8. Documents applicable to all actions relating to a particular pharmaceutical shall be filed only in the appropriate Lead Case, and shall be captioned as follows:

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL 2724
16-MD-2724**

HON. CYNTHIA M. RUFE

IN RE: [PHARMACEUTICAL NAME] CASES

16-[XX]-27240

THIS DOCUMENT RELATES TO:

ALL [PHARMACEUTICAL NAME] ACTIONS

DRAFT PROPOSED PRETRIAL ORDER

9. Documents applicable only to a certain Plaintiff Class shall be filed in each appropriate Class Case and shall be captioned as follows:

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL 2724
16-MD-2724
HON. CYNTHIA M. RUFÉ

IN RE: [PHARMACEUTICAL NAME] CASES

THIS DOCUMENT RELATES TO:

ALL [PLAINTIFF CLASS OR GROUP] ACTIONS

16-[XX]-2724[X]

10. Documents applicable only to an Individual Case shall be filed both in the Individual Case and the applicable Lead Case, and shall be captioned as follows:

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION

MDL 2724
16-MD-2724
HON. CYNTHIA M. RUFÉ

IN RE: [PHARMACEUTICAL NAME] CASES

16-[XX]-27240

THIS DOCUMENT RELATES TO:

Civil Action No.

[Name of Plaintiff] v. [Name of First Defendant]

[XX]-cv-[XXXX]

11. No later than **June 9, 2017**, Lead Plaintiffs' Counsel shall file in each Lead Case and Class Case a Notice setting forth all Individual Cases that fall within the Lead Case or Class Case.

DRAFT PROPOSED PRETRIAL ORDER

12. No later than **June 16, 2017**, Defense Liaison Counsel shall file in each Lead Case and Class Case a Notice setting forth all Defendants that have been named in any Individual Cases that fall within the Lead Case or Class Case.

13. No later than **June 23, 2017**, all counsel shall enter appearances in each Lead Case or Class Case in which they represent client[s]. All counsel associated with the same law firm and representing the same client[s] shall enter a joint entry of appearance.

14. New actions filed into the MDL shall list on the Civil Cover Sheet as related cases the Master Docket, Lead Case, and Class Case.

It is so **ORDERED**.

BY THE COURT:

CYNTHIA M. RUFÉ, J.

DRAFT